Stephen E. Congly , Mayur Brahmania , Carla S. Coffin
{"title":"医疗补助受益人用于治疗乙型肝炎的核苷（t）ide 类似物支出：2012-2021 年。","authors":"Stephen E. Congly , Mayur Brahmania , Carla S. Coffin","doi":"10.1016/j.aohep.2024.101509","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Treatment of chronic hepatitis B (CHB) with nucelos(t)ide analogues (NA) can improve outcomes, but NA treatment is expensive for insurance plans.</p></div><div><h3>Materials and Methods</h3><p>The Centers for Medicare & Medicaid Services database was assessed from 2012 to 2021 to assess the use of NA for CHB in patients on Medicaid. Data extracted included the number of claims, units, and costs of each agent stratified by originator and generic.</p></div><div><h3>Results</h3><p>Over the study period, 1.9 billion USD was spent on NA, with spending peaking in 2016 at $289 million US, which has subsequently decreased. Lower expenditures since 2016 have been associated with increased use of generics. The use of generic tenofovir or entecavir led to savings of $669 million US over the study period.</p></div><div><h3>Conclusions</h3><p>Increased generic use has significantly reduced expenditures for NA drugs; policy shifts towards generic drug use may help with sustainability.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 4","pages":"Article 101509"},"PeriodicalIF":3.7000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S166526812400303X/pdfft?md5=80b949017c82b0852edaae9546714f2f&pid=1-s2.0-S166526812400303X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Spending on nucleos(t)ide analogues for hepatitis B in medicaid beneficiaries: 2012-2021\",\"authors\":\"Stephen E. Congly , Mayur Brahmania , Carla S. Coffin\",\"doi\":\"10.1016/j.aohep.2024.101509\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction and Objectives</h3><p>Treatment of chronic hepatitis B (CHB) with nucelos(t)ide analogues (NA) can improve outcomes, but NA treatment is expensive for insurance plans.</p></div><div><h3>Materials and Methods</h3><p>The Centers for Medicare & Medicaid Services database was assessed from 2012 to 2021 to assess the use of NA for CHB in patients on Medicaid. Data extracted included the number of claims, units, and costs of each agent stratified by originator and generic.</p></div><div><h3>Results</h3><p>Over the study period, 1.9 billion USD was spent on NA, with spending peaking in 2016 at $289 million US, which has subsequently decreased. Lower expenditures since 2016 have been associated with increased use of generics. The use of generic tenofovir or entecavir led to savings of $669 million US over the study period.</p></div><div><h3>Conclusions</h3><p>Increased generic use has significantly reduced expenditures for NA drugs; policy shifts towards generic drug use may help with sustainability.</p></div>\",\"PeriodicalId\":7979,\"journal\":{\"name\":\"Annals of hepatology\",\"volume\":\"29 4\",\"pages\":\"Article 101509\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S166526812400303X/pdfft?md5=80b949017c82b0852edaae9546714f2f&pid=1-s2.0-S166526812400303X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S166526812400303X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S166526812400303X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
简介和目标：使用核苷类似物（NA）治疗慢性乙型肝炎（CHB）可改善疗效，但对于保险计划而言，NA治疗费用昂贵：对美国医疗保险与医疗补助服务中心（Centers for Medicare & Medicaid Services）2012 年至 2021 年的数据库进行了评估，以评估医疗补助计划（Medicaid）患者使用 NA 治疗慢性乙型肝炎（CHB）的情况。提取的数据包括按原研药和非专利药分层的每种药物的索赔数量、单位和费用：在研究期间，NA的支出为19亿美元，2016年达到峰值，为2.89亿美元，随后有所下降。2016 年以来支出的减少与仿制药使用的增加有关。在研究期间，使用仿制药替诺福韦或恩替卡韦节省了6.69亿美元：非专利药使用的增加大大降低了NA药物的支出；政策向非专利药使用的转变可能有助于实现可持续性。
Spending on nucleos(t)ide analogues for hepatitis B in medicaid beneficiaries: 2012-2021
Introduction and Objectives
Treatment of chronic hepatitis B (CHB) with nucelos(t)ide analogues (NA) can improve outcomes, but NA treatment is expensive for insurance plans.
Materials and Methods
The Centers for Medicare & Medicaid Services database was assessed from 2012 to 2021 to assess the use of NA for CHB in patients on Medicaid. Data extracted included the number of claims, units, and costs of each agent stratified by originator and generic.
Results
Over the study period, 1.9 billion USD was spent on NA, with spending peaking in 2016 at $289 million US, which has subsequently decreased. Lower expenditures since 2016 have been associated with increased use of generics. The use of generic tenofovir or entecavir led to savings of $669 million US over the study period.
Conclusions
Increased generic use has significantly reduced expenditures for NA drugs; policy shifts towards generic drug use may help with sustainability.
期刊介绍：
Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
